concept

EPO

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about EPO: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

133Connections

6Hypotheses

0Analyses

50Outgoing

37Incoming

6Experiments

0Debates

Summary

EPO is a concept in neurodegeneration research. Key relationships include: regulates, activates, therapeutic target. Associated with ALS, Als, Asthma. Connected to 87 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	EPO
Key Genes/Proteins	AHR, AKT, AND, ANXIETY, BAX, BCL-2
Related Diseases	Als, ALS, Anxiety, Asthma, Carcinoma
Related Pathways	Akt, Angiogenesis, Blood-Brain Barrier
Linked Hypotheses	1 hypotheses

Pathway Diagram

graph TD
    EPO["EPO"]
    EPO -->|"regulates"| erythropoiesis["erythropoiesis"]
    EPO -->|"regulates"| Als["Als"]
    EPO -->|"activates"| Leukemia["Leukemia"]
    EPO -->|"activates"| Ischemia["Ischemia"]
    EPO -->|"activates"| Ms["Ms"]
    EPO -->|"activates"| Stroke["Stroke"]
    EPO -->|"activates"| Tumor["Tumor"]
    EPO -->|"activates"| Cardiovascular["Cardiovascular"]
    EPO -->|"regulates"| ALS["ALS"]
    FOS["FOS"] -->|"activates"| EPO
    VHL["VHL"] -->|"activates"| EPO
    BAX["BAX"] -->|"activates"| EPO
    ERK["ERK"] -->|"activates"| EPO
    FGF2["FGF2"] -->|"regulates"| EPO
    TLR4["TLR4"] -->|"regulates"| EPO
    PI3K["PI3K"] -->|"regulates"| EPO
    ISG15["ISG15"] -->|"regulates"| EPO
    EPOR["EPOR"] -->|"regulates"| EPO
    CXCL10["CXCL10"] -->|"regulates"| EPO

Outgoing (96)

Target	Relation	Type	Str
erythropoiesis	regulates	biological_process	0.80
TfRMAb-EPO	associated_with	drug	0.70
Als	activates	disease	0.65
Anxiety	activates	disease	0.65
Als	biomarker_for	disease	0.65
Carcinoma	therapeutic_target	disease	0.65
Renal Cell Carcinoma	therapeutic_target	disease	0.65
Tumor	activates	disease	0.65
Cardiovascular	activates	disease	0.65
Tumor	associated_with	disease	0.65
Cardiovascular	therapeutic_target	disease	0.65
Als	regulates	disease	0.65
Leukemia	activates	disease	0.65
Stroke	activates	disease	0.65
ALS	regulates	disease	0.65
Depression	activates	disease	0.65
Asthma	regulates	disease	0.65
Ms	activates	disease	0.65
Als	inhibits	disease	0.65
Inflammation	inhibits	disease	0.65
Ischemia	activates	disease	0.65
NEUROGENESIS	regulates	phenotype	0.65
Pneumonia	regulates	disease	0.65
ISG15	regulates	gene	0.60
FGF2	regulates	gene	0.60
Pi3K/Akt	regulates	pathway	0.60
EPOR	regulates	gene	0.60
TLR4	regulates	gene	0.60
CXCL10	regulates	gene	0.60
AHR	inhibits	gene	0.60
INFLAMMATION	inhibits	gene	0.60
MYD88	regulates	gene	0.60
IFN	associated_with	gene	0.60
Nf-Κb	regulates	pathway	0.60
Nf-Kb	regulates	pathway	0.60
Immune Response	regulates	pathway	0.60
ANXIETY	activates	gene	0.60
Neurogenesis	activates	pathway	0.60
Neuron	causes	cell_type	0.60
Rb	regulates	protein	0.60
Fgf	regulates	protein	0.60
Ubiquitin	regulates	protein	0.60
depression	activates	disease	0.60
JAK2	activates	gene	0.60
STAT5	activates	gene	0.60
JAK-STAT signaling	participates_in	pathway	0.60
JAK2	regulates	gene	0.60
STAT5	regulates	gene	0.60
depression	regulates	disease	0.60
HIF	expressed_in	gene	0.60

Incoming (37)

Source	Relation	Type	Str
AKT	regulates	gene	0.70
PI3K	regulates	gene	0.70
TLR4	regulates	gene	0.70
CXCL10	regulates	gene	0.60
ANXIETY	activates	gene	0.60
ISG15	regulates	gene	0.60
EPOR	regulates	gene	0.60
FGF2	regulates	gene	0.60
PIEZO1	therapeutic_target	gene	0.60
JAK2	therapeutic_target	gene	0.60
VHL	therapeutic_target	gene	0.60
ERK	activates	gene	0.60
LGALS9	regulates	gene	0.60
STAT1	regulates	gene	0.60
CSF2RA	regulates	gene	0.60
ERK	regulates	gene	0.60
S100A8	regulates	gene	0.60
P38	regulates	gene	0.60
CSF2	regulates	gene	0.60
FGF8	regulates	gene	0.60
TSLP	associated_with	gene	0.60
FOS	regulates	gene	0.60
NF-KB	regulates	gene	0.60
NF-ΚB	regulates	gene	0.60
MAPK	regulates	gene	0.60
HSPA1A	regulates	gene	0.60
BCL-2	regulates	gene	0.60
AND	regulates	gene	0.60
GENES	regulates	gene	0.60
NAMPT	regulates	gene	0.60
BAX	activates	gene	0.60
VHL	activates	gene	0.60
JAK2	activates	gene	0.60
CD31	activates	gene	0.60
FOS	activates	gene	0.60
DENTATE GYRUS	associated_with	brain_region	0.45
HIPPOCAMPUS	associated_with	brain_region	0.45

Targeting Hypotheses (6)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Metabolic Switch Targeting for A1→A2 Repolarization	0.726	neurodegeneration	Astrocyte reactivity subtypes in neurode
ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2	0.725	lipidomics	Lipid metabolism dysregulation in Alzhei
Rab12 may better report chronic lysosomal stress biology tha	0.670	neurodegeneration	Do pathogenic LRRK2 mutations amplify vo
EPO Set Point Calibration Hypothesis	0.653	endocrinology	Does TRT-induced erythrocytosis actually
A genetically encoded reporter for axonal mitochondrial prot	0.540	neuroscience	How can subcellular compartmentalization

TYROBP Causal Network Inhibition for Microglial Repolarizati	0.105	neurodegeneration	Neuroinflammation Biomarker Panel for Ea

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (6)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Proposed experiment from debate on Astrocytes adopt A1 (neurotoxic) an	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
Proposed experiment from debate on Microglia activate astrocytes via I	falsification	Neuroinflammation	0.400	0.50	cell_line	proposed	$80,000
Metabolic Pathway-Targeted Therapy in ALS	clinical	ALS	0.400	0.50	human	proposed	$6,550,000
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000
GLP-1 Agonist Responder Prediction Study — Precision Medicine for Neur	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
HK1 and HK2 Beyond Glycolysis: Mitochondrial Interactions and Dual Roles in Meta [PMID:41387352]	Pesce NA, Seminara G, Giarrusso G, Tomas	Adv Biol (Weinh)	2026	1
Glucose Metabolic Reprogramming in Microglia: Implications for Neurodegenerative [PMID:39987285]	Fang M, Zhou Y, He K, Lu Y, Tao F, Huang	Mol Neurobiol	2025	1
Hexokinase 2-mediated metabolic stress and inflammation burden of liver macropha [PMID:40014451]	Li J, Chen X, Song S, Jiang W, Geng T, W	Cell Rep	2025	1
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. [PMID:38904014]	Fontana F, Giannitti G, Marchesi S, Limo	Int J Biol Sci	2024	1
Metabolic phenotype of bladder cancer. [PMID:26975021]	Massari F, Ciccarese C, Santoni M, Iacov	Cancer Treat Rev	2016	1
Aryl hydrocarbon receptor impairs HK2-controlled flux of the hexosamine biosynth [PMID:40582563]	Li S, Zhu J, Song J, Yang L, Gong Y et a	J Adv Res	2026	0
HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis [PMID:41023273]	Mitchell CD, Morris CA, Wild M, Cunningh	Acta Pharmacol Sin	2026	0
Hypoxia-Induced Histone Lactylation Promotes Ferroptosis in Cardiomyocytes via t [PMID:41229334]	Zhu XH, Hou JW, Lv ZY, Sun MH, Zhang XY	Kaohsiung J Med Sci	2026	0
Granzyme B knockdown inhibits NLRP3-mediated pyroptosis and the JAK2/STAT3 signa [PMID:41447776]	Wang M, Chen D, Zhang D, Han H, Xie M et	Tissue Cell	2026	0
Targeting glycolysis in prostate cancer: Molecular mechanisms and therapeutic ad [PMID:41548699]	Zhang J, Zhang T, Song D, Xu D	Biochim Biophys Acta Rev Cance	2026	0
Duzhong-Gegen formula ameliorated hyperuricemia by enhancing renal uric acid exc [PMID:41905095]	Wang L, Gan Y, Huang J, Long L, Li S, Wa	Phytomedicine : international	2026	0
From Phytochemical Characterization to Energy Metabolism-Driven Molecular Respon [PMID:41901183]	Gülüm L, Güler E, Çapkınoğlu E, Çelik AB	Nutrients	2026	0
Investigating the Effect and Mechanism of Protocatechuic Aldehyde on Vascular De [PMID:41897347]	["Xiao T", "Tao J", "Tan J", "Yi X", "Wa	Biomolecules	2026	0
STING Degradation by PRRSV Activates HK2-Mediated Glycolysis to Facilitate Viral [PMID:41902192]	Luo L, Zhou L, Gao X, Li Y, Zhou H, Li Y	Viruses	2026	0
A Novel Dual URAT1/GLUT9 Inhibitor Reduces Hyperuricemia by Enhancing Uric Acid [PMID:41901335]	Zhang H, Huang J, Yang W, Zhou W, Ding J	Pharmaceuticals (Basel, Switze	2026	0
Erchen decoction and its active flavonoids hesperidin and quercetin alleviate hi [PMID:41921767]	Zheng M, Yang K, Ma Y, Suo W, Li J, Huan	Journal of ethnopharmacology	2026	0
Hexokinase 2 interacts with PINK1 to facilitate mitophagy in astrocytes and rest [PMID:40531619]	["Howden J", "Hakansson H", "Nieto-Rostr	Cell reports	2025	0
Protective Effect of alpha-Tocopherol Against Ochratoxin A in Kidney Cell Line H [PMID:36997025]	["Lee H", "Kim H", "Ryu D"]	Journal of food protection	2023	0
Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters. [PMID:33946854]	Ciscato F, Ferrone L, Masgras I, Laquatr	International journal of molec	2021	0
The impact of gender matching between donor and recipient on the outcome of kidn [PMID:31929272]	["Abou-Jaoude M", "El-Helou E", "Nasser	Saudi journal of kidney diseas	2019	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning EPO in their description or question text

TYROBP Causal Network Inhibition for Microglial Repolarization

Score: 0.105 · neurodegeneration · 2026-04-18

## Mechanistic Overview TYROBP Causal Network Inhibition for Microglial Repolarization starts from the claim that modula